The peptide market has a pricing problem. And it has nothing to do with what things actually cost to make.
Pricing in this space is driven by supply constraints, regulatory barriers, and the collective willingness of early adopters to pay for exclusivity. Once supply stabilizes, those prices collapse. We’re betting that collapse is coming. And we’re pricing Catalyst as if it’s already here.
By 2028, we’re committed to a 10% price reduction.
This is not a marketing claim. This is a commitment backed by our cost structure and our confidence in scaling. We price on costs, not on what the market will bear. As we scale, costs drop. When costs drop, prices drop with them.
We don’t raise prices when demand increases. We don’t create artificial scarcity. We don’t run urgency campaigns designed to lock people in at higher rates before the price goes down. These tactics are common in the peptide market. They’re also the opposite of how we operate.
Research peptides shouldn’t require wealth. The science doesn’t care what anyone earns.